• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Ⅰ期非小细胞肺癌行肺叶切除术完全切除后长期生存的预后因素。

Prognostic factors for long-term survival following complete resection by lobectomy in stage I non-small cell lung cancer.

机构信息

Department of Thoracic Surgery, University Center for Thoracic Diseases, University Medical Center Mainz, Johannes Gutenberg University Mainz, Mainz, Germany.

Department of Thoracic Surgery, ViDia Kliniken Karlsruhe, Karlsruhe, Germany.

出版信息

Thorac Cancer. 2022 Oct;13(20):2861-2866. doi: 10.1111/1759-7714.14630. Epub 2022 Aug 30.

DOI:10.1111/1759-7714.14630
PMID:36054161
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9575062/
Abstract

BACKGROUND

The aim of this study was to evaluate predictors for long-term overall survival (OS) in patients with stage I non-small cell lung cancer (NSCLC).

METHODS

All patients undergoing complete resection by lobectomy for stage I NSCLC between October 2012 and December 2015 at a single center were included. Univariable and multivariable Cox regression analyses were performed to identify prognostic factors.

RESULTS

A total of 92 patients were included. Univariable and multivariable Cox regression analyses revealed preoperative neutrophil to lymphocyte ratio (NLR, p = 0.005), preoperative diffusion capacity of the lungs for carbon monoxide (DLCO, p = 0.010) and forced expiratory volume in 1 second (FEV1, p = 0.041) as well as male gender (p = 0.026) as independent prognostic factors for OS. Combining the calculated cutoff values for FEV1 (<73.0%) and NLR (>3.49) into one parameter resulted in a highly significant difference in survival times when stratified by this variable.

CONCLUSIONS

Recently, much emphasis has been put on the prognostic importance of blood biomarkers in NSCLC. In our study, NLR was an independent factor for OS, as were baseline characteristics such as DLCO, FEV1, and gender. Further studies on the association of biomarkers for systemic inflammation and lung function parameters with respect to patient survival are warranted.

摘要

背景

本研究旨在评估 I 期非小细胞肺癌(NSCLC)患者的长期总生存期(OS)的预测因素。

方法

本研究纳入了 2012 年 10 月至 2015 年 12 月在一家中心接受完全肺叶切除术治疗的所有 I 期 NSCLC 患者。采用单变量和多变量 Cox 回归分析确定预后因素。

结果

共纳入 92 例患者。单变量和多变量 Cox 回归分析显示,术前中性粒细胞与淋巴细胞比值(NLR,p=0.005)、术前一氧化碳弥散量(DLCO,p=0.010)和 1 秒用力呼气量(FEV1,p=0.041)以及男性(p=0.026)是 OS 的独立预后因素。将计算出的 FEV1(<73.0%)和 NLR(>3.49)的临界值组合成一个参数,根据该变量分层时,生存时间有显著差异。

结论

最近,人们非常重视 NSCLC 中血液生物标志物的预后重要性。在本研究中,NLR 是 OS 的独立因素,DLCO、FEV1 和性别等基线特征也是 OS 的独立因素。需要进一步研究全身炎症标志物和肺功能参数与患者生存之间的关系。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83b5/9575062/406806fe70c6/TCA-13-2861-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83b5/9575062/6ce3bf5860fd/TCA-13-2861-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83b5/9575062/de32ef97538d/TCA-13-2861-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83b5/9575062/406806fe70c6/TCA-13-2861-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83b5/9575062/6ce3bf5860fd/TCA-13-2861-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83b5/9575062/de32ef97538d/TCA-13-2861-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83b5/9575062/406806fe70c6/TCA-13-2861-g003.jpg

相似文献

1
Prognostic factors for long-term survival following complete resection by lobectomy in stage I non-small cell lung cancer.Ⅰ期非小细胞肺癌行肺叶切除术完全切除后长期生存的预后因素。
Thorac Cancer. 2022 Oct;13(20):2861-2866. doi: 10.1111/1759-7714.14630. Epub 2022 Aug 30.
2
Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.中性粒细胞与淋巴细胞比值(NLR)和血小板与淋巴细胞比值(PLR)作为接受纳武单抗治疗的非小细胞肺癌(NSCLC)患者的预后标志物。
Lung Cancer. 2017 Sep;111:176-181. doi: 10.1016/j.lungcan.2017.07.024. Epub 2017 Jul 24.
3
Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.系统免疫炎症指数、中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值可预测纳武利尤单抗治疗转移性非小细胞肺癌患者的临床结局。
J Clin Lab Anal. 2019 Oct;33(8):e22964. doi: 10.1002/jcla.22964. Epub 2019 Jul 8.
4
Parenchymal preserving anatomic resections result in less pulmonary function loss in patients with Stage I non-small cell lung cancer.保留实质的解剖性切除术可减少Ⅰ期非小细胞肺癌患者的肺功能损失。
J Cardiothorac Surg. 2015 Apr 1;10:49. doi: 10.1186/s13019-015-0253-6.
5
Preoperative platelet to lymphocyte and neutrophil to lymphocyte ratios are independent prognostic factors for patients undergoing lung cancer radical surgery: A single institutional cohort study.术前血小板与淋巴细胞比值及中性粒细胞与淋巴细胞比值是肺癌根治术患者的独立预后因素:一项单中心队列研究。
Oncotarget. 2017 May 23;8(21):35301-35310. doi: 10.18632/oncotarget.13312.
6
The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs.外周血中性粒细胞与淋巴细胞比值是接受表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)治疗的表皮生长因子受体(EGFR)突变的非小细胞肺癌患者生存情况的预后预测指标。
Medicine (Baltimore). 2018 Jul;97(30):e11648. doi: 10.1097/MD.0000000000011648.
7
Diffusion lung capacity for carbon monoxide (DLCO) is an independent prognostic factor for long-term survival after curative lung resection for cancer.一氧化碳弥散量(DLCO)是癌症根治性肺切除术后长期生存的独立预后因素。
J Surg Oncol. 2009 Dec 15;100(8):703-7. doi: 10.1002/jso.21407.
8
The postoperative neutrophil-to-lymphocyte ratio and changes in this ratio predict survival after the complete resection of stage I non-small cell lung cancer.术后中性粒细胞与淋巴细胞比值及其变化可预测Ⅰ期非小细胞肺癌完全切除术后的生存情况。
Onco Targets Ther. 2016 Oct 21;9:6529-6537. doi: 10.2147/OTT.S117290. eCollection 2016.
9
Marginal pulmonary function should not preclude lobectomy in selected patients with non-small cell lung cancer.边缘性肺功能不应排除选择性非小细胞肺癌患者行肺叶切除术。
J Thorac Cardiovasc Surg. 2014 Feb;147(2):738-44; Discussion 744-6. doi: 10.1016/j.jtcvs.2013.09.064. Epub 2013 Nov 16.
10
Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non-small-cell lung cancer treated with chemoradiotherapy.免疫炎症生物标志物对预测接受放化疗的非小细胞肺癌患者生存和放疗敏感性的预后影响。
J Med Imaging Radiat Oncol. 2022 Feb;66(1):146-157. doi: 10.1111/1754-9485.13341. Epub 2021 Oct 10.

引用本文的文献

1
The value of 18F-FDG PET/CT combined with 3D quantitative technology and clinicopathological features in predicting prognosis of NSCLC.18F-FDG PET/CT联合3D定量技术及临床病理特征在预测非小细胞肺癌预后中的价值
Front Oncol. 2025 Apr 8;15:1533569. doi: 10.3389/fonc.2025.1533569. eCollection 2025.
2
The advanced lung cancer inflammation index (ALI) predicted the postoperative survival rate of patients with non-small cell lung cancer and the construction of a nomogram model.高级肺癌炎症指数 (ALI) 预测了非小细胞肺癌患者的术后生存率和列线图模型的构建。
World J Surg Oncol. 2024 Jun 14;22(1):158. doi: 10.1186/s12957-024-03432-3.
3

本文引用的文献

1
Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer.全身炎症标志物可预测非小细胞肺癌一线免疫检查点抑制剂的生存情况。
ESMO Open. 2022 Apr;7(2):100445. doi: 10.1016/j.esmoop.2022.100445. Epub 2022 Apr 7.
2
The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors.中性粒细胞与淋巴细胞比值/血小板与淋巴细胞比值/淋巴细胞与单核细胞比值与免疫检查点抑制剂治疗的非小细胞肺癌患者生存预后的关系。
Medicine (Baltimore). 2022 Jan 21;101(3):e28617. doi: 10.1097/MD.0000000000028617.
3
[Correlation Analysis of Ki67 Expression and EGFR Mutation on the Risk of Recurrence and Metastasis in Postoperative Patients with Stage I Lung Adenocarcinoma].
[Ki67表达与EGFR突变对Ⅰ期肺腺癌术后患者复发和转移风险的相关性分析]
Zhongguo Fei Ai Za Zhi. 2022 Dec 20;25(12):852-861. doi: 10.3779/j.issn.1009-3419.2022.101.55.
Revisiting neoadjuvant therapy in non-small-cell lung cancer.
重新审视非小细胞肺癌的新辅助治疗。
Lancet Oncol. 2021 Nov;22(11):e501-e516. doi: 10.1016/S1470-2045(21)00383-1.
4
Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Locally Advanced Non-small-cell Lung Cancer Treated with Trimodality Therapy.中性粒细胞与淋巴细胞比值对局部晚期非小细胞肺癌行三联序贯治疗的预后意义。
Ann Surg Oncol. 2021 Sep;28(9):4880-4890. doi: 10.1245/s10434-021-09690-9. Epub 2021 Feb 25.
5
A comparison of inflammation markers for predicting oncological outcomes after surgical resection of non-small-cell lung cancer: a validated analysis of 2,066 patients.一项比较炎症标志物以预测非小细胞肺癌手术后肿瘤学结局的研究:对 2066 例患者的验证性分析。
Sci Rep. 2020 Nov 11;10(1):19523. doi: 10.1038/s41598-020-76644-8.
6
Clinical significance of preoperative inflammatory markers in non-small cell lung cancer patients: A multicenter retrospective study.术前炎症标志物在非小细胞肺癌患者中的临床意义:一项多中心回顾性研究。
PLoS One. 2020 Nov 2;15(11):e0241580. doi: 10.1371/journal.pone.0241580. eCollection 2020.
7
Preoperative platelet-lymphocyte ratio is a superior prognostic biomarker to other systemic inflammatory response markers in non-small cell lung cancer.术前血小板与淋巴细胞比值是预测非小细胞肺癌预后的一项优于其他全身炎症反应标志物的生物标志物。
Medicine (Baltimore). 2020 Jan;99(4):e18607. doi: 10.1097/MD.0000000000018607.
8
Peripheral Blood Lymphocytes and Platelets Are Prognostic in Surgical pT1 Non-Small Cell Lung Cancer.外周血淋巴细胞和血小板与手术治疗的 pT1 期非小细胞肺癌患者的预后相关。
Ann Thorac Surg. 2020 Feb;109(2):337-342. doi: 10.1016/j.athoracsur.2019.09.006. Epub 2019 Oct 5.
9
Prognostic value of neutrophil-to-lymphocyte, platelet-to-lymphocyte and lymphocyte-to-monocyte ratio ratios in patients operated on due to non-small cell lung cancer.中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值及淋巴细胞与单核细胞比值在非小细胞肺癌手术患者中的预后价值
J Thorac Dis. 2019 Aug;11(8):3377-3384. doi: 10.21037/jtd.2019.07.72.
10
Elevated pretreatment platelet-to-lymphocyte ratio is associated with poor survival in stage IV non-small cell lung cancer with malignant pleural effusion.升高的预处理血小板与淋巴细胞比值与伴恶性胸腔积液的 IV 期非小细胞肺癌患者的不良生存相关。
Sci Rep. 2019 Mar 18;9(1):4721. doi: 10.1038/s41598-019-41289-9.